Skip to main content
21 January 2021
Last updated:
Thursday 21 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

MorphoSys Q3 results lifted by launch

Monday 16 November 2020
Country

Germany

MorphoSys AG nearly doubled revenue in the third quarter as it reaped the first benefits from its newly launched cancer treatment Monjuvi (tafasitamab).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Company News

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

T-knife appoints Thomas Soloway as chief executive
Thursday January 21 2021
Domainex makes two executive appointments
Thursday January 21 2021
Richard Francis named CEO of Purespring
Tuesday January 19 2021
Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.